AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06409143 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tES
Description: The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
Study NCT06409143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UE rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
Study NCT05360134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carica Papaya Leaf Extract
Description: Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
Study NCT05360134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in a similar manner
Study NCT05601167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir/ritonavir
Description: Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
Study NCT06409143 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: UE rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
Study NCT06409143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tES (Bilateral)
Description: The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.
Study NCT05005390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTIP ventilation
Description: In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
Study NCT05005390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTIP ventilation
Description: In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
Study NCT05005390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask Ventilation
Description: In mask ventilation, a mask is placed over the nose and mouth.
Study NCT05005390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask Ventilation
Description: In mask ventilation, a mask is placed over the nose and mouth.
Study NCT04871295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight
Description: Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
Study NCT06344819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves insertion of thin filiform needles (gauze 30-40) at certain points on the body.
Study NCT06344819 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: During sham acupuncture, the point on the participant's thigh 6 inches proximal to the ST36 acupuncture point is gently tapped with an acupuncture needle guide tube and an acupuncture needle is taped flat to the skin. This point is not on any acupuncture meridian or point.
Study NCT05391906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Description: Diffusion-weighted magnetic resonance imaging
Study NCT04748614 — intervention group
Intervention type: OTHER
Intervention: Cost
Description: ICU cost
Study NCT05601167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study
Study NCT06585761 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: patients with HF are subjected to regular dose of SGLT2I member according to patient status.
Study NCT06585761 — intervention group
Intervention type: DEVICE
Intervention: echo cardiogram
Description: the patients are subjected to ECHO to determine their EF prior to and post the study
Study NCT06536569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal limiting membrane (ILM) Peeling with Sharkskin Forceps
Description: 25g Grieshaber Sharkskin ILM Forceps with Reflex Handle
Study NCT06536569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal limiting membrane (ILM) Peeling with Standard Forceps
Description: 25g Grieshaber Standard ILM Forceps
Study NCT05156957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapeutic intervention
Description: The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
Study NCT05731479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diathermy + exercise group
Description: The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
Study NCT05731479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diathermy placebo + exercise group
Description: The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
Study NCT05454657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback + treatment as usual
Description: Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
Study NCT05454657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual only
Description: Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
Study NCT05454657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual only
Description: Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
Study NCT05472883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood samples
Description: - Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
Study NCT05472883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collection of body tissues
Description: removal of intra-abdominal fat and muscle tissue
Study NCT04890054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Immunochemical Test
Description: Patients due for CRC screening are mailed a FIT test by the clinic or health plan
Study NCT04890054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interviews to evaluate the implementation of the mailed FIT and patient navigation programs by the clinics and regional organizations
Study NCT04890054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Clinic staff are trained in Navigation, patients with an abnormal FIT are contacted about colonoscopy by patient navigators
Study NCT05211206 — intervention group
Intervention type: OTHER
Intervention: IV fluids
Description: Amount of intravenous fluids delivered
Study NCT04685564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission.
Study NCT04685564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the same as RBD1016
Study NCT06290310 — intervention group
Intervention type: DEVICE
Intervention: EIT
Description: continuous electric impedance tomography measurement
Study NCT06290310 — intervention group
Intervention type: DEVICE
Intervention: patient-ventilator asynchrony assessment
Description: patient-ventilator asynchrony assessment by flow/time curve and machine learning
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IM
Description: In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IM
Description: In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IM
Description: In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IM
Description: In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IV
Description: In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IV
Description: In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
Study NCT05437289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
Study NCT05324163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002 Spray
Description: X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
Study NCT05324163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib capsules
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
Study NCT05324163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
Study NCT05324163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
Study NCT05324163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
Study NCT05691231 — intervention group
Intervention type: DEVICE
Intervention: NuVasive Simplify Cervical Artificial Disc
Description: Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
Study NCT05472883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine care procedure
Description: * Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~* clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~* dosage of ß HCG for womens.
Study NCT06704516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy
Description: Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)
Study NCT06713746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: growth differentiation factor 15
Description: rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta
Study NCT06713967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metformin (Glucophage)
Description: In this intervention, participants will receive oral metformin (500 mg daily, gradually increasing to 1500 mg daily for non-obese participants and 2000 mg daily for obese participants) starting from the second week of pregnancy and continuing until delivery. Metformin will be administered in combination with a standard diet and exercise plan. The intervention aims to evaluate the impact of metformin on pregnancy outcomes in women with polycystic ovarian syndrome (PCOS), focusing on reducing complications such as early pregnancy loss, preterm delivery, gestational diabetes, and intrauterine growth restriction. Participants will be regularly monitored with follow-up visits, ultrasounds, and glucose tests to assess the effectiveness of the treatment.
Study NCT04748926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: caplet Route of administration: oral
Study NCT06713967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (Diet and Exercise Only)
Description: In this intervention, participants will receive a standard diet and exercise plan designed to promote a healthy pregnancy. This intervention does not include any pharmacological treatment, such as metformin. The goal is to evaluate the pregnancy outcomes in women with polycystic ovarian syndrome (PCOS) managed with lifestyle modifications alone, without the added effect of medication. Participants will be monitored through regular follow-up visits, ultrasounds, and glucose tests to track pregnancy progress, including the occurrence of gestational diabetes, preterm delivery, early pregnancy loss, and fetal growth restriction.
Study NCT06722703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shock wave lithotripsy
Description: Extracorporeal shock wave lithotripsy will be performed using a third-generation electromagnetic lithotripter The focal depth is 110 mm; the focal area is 7 mm (radial) and 45-50 mm (axial), and the focal pressure is 6-30 MPa). The procedure is performed in a supine or prone position without anesthesia. Stone localization and simultaneous real-time monitoring during the process will be performed by ultrasound). The shock frequency is 60-90 (shock waves/min). The total number of shock waves applied for one session is between 1500 and 2500 waves, or the session is stopped at a significant stone fragmentation is detected. The voltage applied per session ranged from 10 to 16 kV with stepwise power ramping strategy. All procedures in the SWL group are outpatient procedures.
Study NCT06722703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible ureteroscope lithotripsy
Description: All F-URS cases will be performed by a single surgeon (HMI). A guidewire is placed in the upper urinary tract through a rigid cystoscope under fluoroscopic guidance. An 8-10 F dual lumen catheter is used to dilate the intramural ureter and to fix a second guidewire with hydrophilic coat. The 7.5 F flexible ureteroscope is passed into the upper urinary tract in a monorail fashion over the second wire. A holmium-YAG laser is used at an energy setting of 0.8-1 J and a rate of 10-15 Hz. A 200 µm laser fibre is used for delivering laser energy to the stones. A 2.2 F tipless nitinol basket is used to displace the stones from the lower pole to an upper pole calyx before disintegration. Adequate fragmentation is considered when fragments are smaller than the diameter of the guide wire. Stone fragments will be left for spontaneous passage. At the end of the procedure, the whole collecting system will be inspected for residual stones and a double pigtail ureteric stent will be left for 2 weeks t
Study NCT06156254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)
Description: Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
Study NCT04748926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
Study NCT04748926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
Study NCT06383507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHT101
Description: After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
Study NCT05959837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Rowing Exercise
Description: Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
Study NCT05602961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-COV2-043
Description: COVID-19 vaccine, administered as a booster
Study NCT05602961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2/COMIRNATY®
Description: active control
Study NCT06724484 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical management of fracture
Description: Surgical management of fracture
Study NCT06724484 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06723106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY121
Description: Injection
Study NCT06724107 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: UVC
Description: It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.
Study NCT06724107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVC
Description: It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.